NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
23/03/2026
Voltar para busca
Dado oficial do USPTO
IPSOGEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
45
Atualização mais recente
24/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9
Data de depósito
20/02/2002
Data de registro
07/06/2005
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/03/2026
Última transação
24/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
1
Tipo de titular
11
Localização do titular
HILDEN, DE
Examinador
CASE, LEIGH CAROLINE
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
QIAGEN GMBH
QIAGEN MARSEILLE S.A.S.
Q. M. (pessoa física)
IPSOGEN
Representantes
Daniel M. Gurfinkel Dennemeyer & Associates, LLC
Classificação técnica
Classes Nice
Classe 5Classe 9
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Biological reagents for diagnoses and for identification of biological systems ; pharmaceutical productspreparationschemical preparations and chemico-pharmaceutical preparations for treating illnessesgenetic and infectious illnesses namelyacute leukemiaacute lymphoblastic leukemiaacute myelogenous leukemiaAMLacute monocytic leukemiaAMLacute promyelocytic leukemiaAPLadenocarcinomaadenocarcinoma lung canceradenocystic carcinomaadenoid cystic breast canceradenoid cystic arcinomaadrenal gland canceradvanced breast canceraggressive breast cancerameloblastomaanalanus cancer; angiosarcomaappendix cancerappendiceal cancerastrocytomaarrett's esophagusbartholin gland cancerbasal cell carcinomabasal cell skin cancerB-cell lymphomabilateral breast cancerbile duct cancerbladder cancerbladder metastasesbone cancerbone marrow transplantationBowen's diseasebone metastasesborderline ovarian cancerbrain metastasesbrain tumorbrainstem gliomabreast cancerbreast reconstructionbronchial cancerbronchioalveolar lung cancerbuttock cancercancer of unknown primary siteCUPScancer preventioncarcinoma of unknown primarycarcinoidcarcinoid syndromecarcinoid tumorcarcinosarcomacavernous sinus cancercecum cancercentral nervous system lymphomacentrocytic lymphomacerebral astrocytomacervix cancercervical cancerchest tumorsmediastinum tumorschiasmal gliomachildhood cancerschondromaintracranialchordomachondrosarcomachorioadenoma destruenschoroids plexus carcinomachoroidal melanomachronic leukemiachronic lymphocytic leukemiaCLLchronic myelogenous leukemiaCMLclear cell ovarian cancerclear cell sarcomaCNS lymphomacolon canceradenocarcinoma of the colonadenomatous polypspolypscolorectal cancercraniopharyngiomacutaneous T-cell lymphomaDCIS - ductal carcinoma in situdermatofibrosarcoma protuberansdesmoidtumordesmoplastic tumordiffuse lymphomadiffuselarge-cell lymphomaductal carcinoma in situDCISduodenalcancer dysgerminomaearly stage prostate cancerendocrine cancerendometrial cancerendometrial stromal sarcomaependymomaesophagus canceresophageal canceresophagus cancer of the gastroesophageal junctionesthesioneuroblastomaEwing's sarcomaextensive stage small cell lung cancerextrahepatic bile duct cancerextraskeletal chondrosarcomaextraskeletal Ewing's sarcomaextraskeletal osteosarcomaeye metastaseseye cancerfallopian tube cancerfibrosarcomafibrous histiocytomafollicular lymphomafollicularsmall-cleaved cell lymphomagallbladder cancergastric cancergastrinomagastro-esophagealGE junctioncancergastrointestinal lymphomaGE junction esophageal cancergerm cell tumorgestational trophoblastic diseasegiant cell bone tumorglioblastomagliomagliomatosisgranular lymphocytic lymphomagranulocytic leukemiagranulosa cell ovarian cancerhairy cell leukemiahead and neck cancerhemangioendotheliomahemangiopericytomahepatocelluar carcinomahigh-grade lymphomahigh-risk breast cancerhistiocytomamalignantHodgkin's diseaseHodgkin's disease in pregnancyhormone-refractory prostate cancerin situ breast cancerinsulinomaintermediate-grade lymphomaintraocular melanomainvasive lobular breast cancerislet cell pancreatic cancerKaposi's sarcomakidney cancerkrukenberg tumorlarge-cell lung cancerlarge-cell lymphomalarge-celldiffuse lymphomalarynx cancerlaryngeal cancerleiomyosarcomalentigo malignaleukemialinitis plasticalimited stage small cell lung cancerlip cancerliposarcomaliver cancerrecurrent liver cancerundifferentiated liver cancerlobular carcinoma in situLCISlobular hyperplasia low-grade lymphomalung cancernon-small cell lung cancerepidermoid carcinomalarge cell carcinomasquamous cell carcinomaspindal cell variantpancoast tumorssuperior sSulcus tumorsundifferentiated carcinomalung metastaseslymph node excisionlymphangitic metastasislymph node metastaseslymphoblastic leukemialymphoblastic lymphomalymphocytic lymphomalymphomanon-Hodgkin's lymphomamalignant ascitesmalignant hemangiopericytomamalignant fibrous histiocytomamalignant peripheral nerve sheath tumormalignant pleural effusionmalignant schwannomaMALT lymphomamantle cell lymphomamedlastinal tumormedulloblastomamelanomameningeal cancermeningeal metastasesmeningiomamerkel cell carcinomamerkel cell skin cancermesotheliomamesenchymal chondrosarcomametastatic melanomamixed mullerian tumormucinous carcinomamultiple myelomamuscle-invasive bladder tumormycosis fungoidesmyelodysplasiamyelodysplastic syndromemyelomaBence-Jonesmyeloproliferative disordernail/nail bed cancernasal cavity cancernasopharynx cancerneckradical dissectionneoplastic meningitisnerve sheath tumorsneuroblastomaneuroendocrine tumoradenosquamous carcinomaadenocarcinomaocular melanomaolfactory canceroligodendrogliomaoptic gliomaoral cancerorbital lumphomaorophaiynx cancerosteogenic sarcomaosteosarcomaovarian cancerPagets disease of the breastpancreatic cancerrecurrent pancreatic cancerborderline pancreatic tumorsmucinous cystic tumor with dysplasiaintraductal papillary mucinous tumor with dysplasiapseudopapillary solid tumorislet cell tumorsgastrinomaparagangliomaparanasal sinus cancerparaneoplastic syndromesparathyroid cancerparotid gland cancerpelvic tumorpenis cancerperiampullary cancerpericardial effusionperipheral nerve sheath tumorperipheral T-cell lymphomaperitoneal cancerextraovarian serous carcinomaextraovarian peritoneal serious papillary carcinomaserous surface carcinoma of the peritoneumserous surface papillary carcinomapapillary serous carcinoma of the peritoneummultiple focal peritoneal papillary carcinomaprimary peritoneal papillary serous adenocarcinomaperitoneal carcinomatosispheochromocytomapinealomapineoblastomaplasmacytomapleura cancerpleura metastasespreleukemiaprimary central nervous system lymphomaprimitive neuroctodermal tumorPNETplolymphocytic leukemiapromyelocytic leukemiaprophylactic mastectomyprostate cancerprostatic intraepithelial neoplasiaPINPSApseudomyxoma peritoneirectal cancerrecurrent colon cancerrecurrent colorectal cancerrecurrent lung cancerrecurrent melanomarecurrent ovarian cancerrecurrent prostate cancerrecurrent rectal cancerrelapsed lymphomarenal cell carcinomarenal pelvis cancerretinoblastomarhabdomyosarcomaRichters syndromerising PSA as an indication of recurrent prostate cancersalivary gland cancersarcoma of bonesarcomatoid carcinoma; sebaceous carcinomasezary syndromesinuscavernoussinus cancerskin cancerskin metastasessmall cell bladder cancersmall cell lung cancersmall cleaved cell lymphomasmall intestine cancersoft tissue lymphomasoft tissue sarcomasynovial sarcomaspinal cord cancerspindle cell thyroid cancersquamous cell cancernon-skinsquamous cell lung cancersquamous cell skin cancerstem cell transplantationstomach cancersuperficial bladder cancersweat glands cancerT-cell leukemiaT-cell lymphomacutaneoustesticular cancertestis cancerthalamuthalamicbrain tumorthymomathymus gland cancerthyroid cancerthyroid lymphomatongue cancertongue base cancertransitional cell cancer of renal pelvistransitional cell cancer of the ureterunknown primary cancerureter cancerurethra canceruterine canceruterine sarcomavagina cancervocal cord cancervulva cancerWaldenstrom's macroglobulinemiaWarthin's tumorWilms' tumorZollinger-Ellis syndrome
Classe 9
Information processing devicescomputer keyboardsmousemonitorsreadersdata processing equipmentcompact disc playersoptical character readerscomputer memoriesprinters for use with computersprocessors; computer programs and software for stockagemanagementanalysis of biological information
Publicações
Histórico de despachos e eventos da marca no USPTO.
45 publicações encontradas
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
23/03/2026
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
23/03/2026
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
11/03/2026
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
04/03/2026
PR89
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
13/09/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
13/09/2025
E89R
TEAS SECTION 8 & 9 RECEIVED
14/05/2025
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
07/06/2024
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
24/09/2020
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
15/12/2015
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
15/12/2015
9G8P
REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8
15/12/2015
8PRT
REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED
15/12/2015
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
15/12/2015
E89R
TEAS SECTION 8 & 9 RECEIVED
19/10/2015
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
07/10/2015
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
14/07/2011
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
14/07/2011
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
14/07/2011
E815
TEAS SECTION 8 & 15 RECEIVED
02/06/2011
R.PR
REGISTERED-PRINCIPAL REGISTER
07/06/2005
PUBO
PUBLISHED FOR OPPOSITION
15/03/2005
NPUB
NOTICE OF PUBLICATION
23/02/2005
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
21/10/2004
ALIE
ASSIGNED TO LIE
19/10/2004
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/10/2004
ACEC
AMENDMENT FROM APPLICANT ENTERED
07/10/2004
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/09/2004
PAPER RECEIVED
22/09/2004
CNRT
NON-FINAL ACTION MAILED
04/06/2004
1.BD
Sec. 1(B) CLAIM DELETED
26/04/2004
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/04/2004
PAPER RECEIVED
26/04/2004
CNRT
NON-FINAL ACTION MAILED
23/10/2003
CFIT
CASE FILE IN TICRS
13/09/2003
CNSL
LETTER OF SUSPENSION MAILED
21/02/2003
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/12/2002
PAPER RECEIVED
13/12/2002
CNRT
NON-FINAL ACTION MAILED
19/06/2002
UNPR
UNRESPONSIVE/DUPLICATE PAPER RECEIVED
17/06/2002
DOCK
ASSIGNED TO EXAMINER
14/06/2002
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
15/03/2002
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/03/2002
PAPER RECEIVED
15/03/2002
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace IPSOGEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.